111, Inc. Announces Receipt of Notification from Nasdaq
SHANGHAI, Sept. 27, 2024 /PRNewswire/ — 111, Inc. (“111” or the “Company”) (NASDAQ: YI), a leading tech-enabled healthcare platform... Read more.
Mid-Atlantic Technology Summit for First Responders to Focus on Francis Scott Key Bridge Collapse
BALTIMORE, Sept. 27, 2024 /PRNewswire/ — Join us for the Equipped Mid-Atlantic Technology Summit on Wednesday, October 9, 2024, at the World Trade Center in... Read more.
Source Agriculture Corp Signs agreement with RWE Clean Energy Development LLC to Install Wind Turbines on Illinois Farm
CHICAGO, IL, Sept. 27, 2024 /PRNewswire/ – Source Agriculture Corp is pleased to announce the signing of a strategic agreement with RWE Clean Energy Development... Read more.
Air Force Band of the Golden West Performing in Oregon
EUGENE, Ore., Sept. 27, 2024 /PRNewswire/ — The Air Force Band of the Golden West Clarinet Quartet, will be performing the following FREE patriotic and contemporary... Read more.
Jacobs Advances Strategic Transformation with Completion of Previously Announced Spin-off and Merger
Jacobs retains its innovative, next-generation data solutions and digital technologies business Newly streamlined portfolio enables company to focus on distinct... Read more.
AT&T Declares Dividends on Common and Preferred Shares
DALLAS, Sept. 27, 2024 /PRNewswire/ — The board of directors today declared a quarterly dividend of $0.2775 per share on the company’s common shares,... Read more.
Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Data showed a 91% ORR with P-BCMA-ALLO1 in an optimized lymphodepletion arm, including a 100% ORR in BCMA-naïve patients, and an 86% ORR in those who had received... Read more.
CARVYKTI® is the first and only cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line
45 percent reduction in risk of death achieved with CARVYKTI® after three-year follow-up in landmark CARTITUDE-4 study Data featured in a late-breaking oral presentation... Read more.
FDA Roundup: September 27, 2024
SILVER SPRING, Md., Sept. 27, 2024 /PRNewswire/ — Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the... Read more.
Quidax Launches $125,000 Crypto Innovation Pitch, Partners with Moonshot for TC Battlefield
LAGOS, Nigeria, Sept. 27, 2024 /PRNewswire/ — Quidax and TechCabal have announced a partnership for this year’s TechCabal Battlefield competition. As... Read more.